Kate Niazi-Sai

Senior Director, Corporate Affairs—Solid Biosciences

Sessions:

---

• Simplifying complex topics to make difficult subjects more understandable for all the audiences you need to reach
  Main Conference

  ---

Kate Niazi-Sai is the Senior Director, Corporate Affairs at Solid Biosciences, a clinical-stage, public biotechnology company focused on developing and delivering therapies for Duchenne muscular dystrophy. In her role, Kate is responsible for both external and internal communications strategy with the goal of delivering a consistent and compelling narrative across corporate stakeholders.

Prior to joining Solid, Kate spent more than six years at Biogen where she held multiple roles in pipeline, product and corporate communications. During her tenure, Kate led communications strategy for the company’s Multiple Sclerosis franchise, notability surrounding the approval and launch of its leading therapy, TECFIDERA®.  In addition, Kate managed Biogen’s corporate communications and served as media spokeswoman for the company. Most recently, she was the Public Affairs lead for Biogen’s Rare Disease Group, primarily focused on communications for its late-stage candidate for Spinal Muscular Atrophy (SMA).